TriangleZanzalintinib (NCT06959511)
Zanzalintinib trial for Neoadjuvant Treatment (NCT06959511). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with locally advanced differentiated, poorly differentiated, or RET-negative medullary thyroid cancer, with no prior tyrosine kinase inhibitor treatment.
The idea: daily oral zanzalintinib blocks growth and blood-vessel signals. Researchers test whether it shrinks tumors and makes surgery less complex. Surgery follows if the tumor becomes removable. Distant spread is allowed; additional selection rules apply.
This phase 2 study plans 45 patients. Mark Zafereo leads at MD Anderson in Houston, with four recruiting US sites listed.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.